ORS-ORS-24-002: Overdose Response Strategy Pilot Projects: Interventions to Prevent Overdose at the Intersection of Public Health and Public Safety
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Office of National Drug Control Policy notices from 2024.
Office of National Drug Control Policy offered grants of up to $1.2 million to nonprofits. It expected to make one award. Applications closed on August 30, 2024.
From the official notice on Grants.gov, last changed July 30, 2024. Checked November 7, 2026.
- Award ceiling$1.2 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | July 30, 2024 |
|---|---|
| Deadline | August 30, 2024 |
| Archived by Grants.gov | September 29, 2024 |
Who can apply
This opportunity was open to nonprofits.
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Is this a realistic fit?
- Past Research and Data Analysis awards averaged $915,665; this notice allows up to $1.2 million per award.
- Most of the program's money (65% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The Office of National Drug Control Policy (ONDCP), Executive Office of the President, is seeking applications from a non-profit entity as described in Section 501(c)(3) of the Internal Revenue Code with expert knowledge and extensive experience in: (1) Supporting the development and implementation of local pilot projects to reduce overdose and related harms for individuals interacting with first responders and the criminal justice system; and (2) Working collaboratively with multi-sector partners and people with lived and living experience to innovative strategies at the intersection of public health and public safety that focus on saving lives and reducing harm.
Who has won Research and Data Analysis grants before
From fiscal 2021 to 2025, Research and Data Analysis (95.007) awarded $9.2 million across 10 grant awards, an average of $915,665 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Baltimore | Maryland | 2 | $5.9 million |
| National Association of County and City Health Officials | District of Columbia | 1 | $1.2 million |
| National Foundation for the Centers for Disease Control & Prevention, Inc. | Georgia | 1 | $700,000 |
| University of Maryland, College Park | Maryland | 3 | $574,998 |
| American College of Medical Toxicology, Inc. | Arizona | 1 | $400,000 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is ORS-ORS-24-002 still open?
No. It closed on August 30, 2024.
Who can apply for Overdose Response Strategy Pilot Projects: Interventions to Prevent Overdose at the Intersection of Public Health and Public Safety?
Office of National Drug Control Policy accepted applications from nonprofits.
What is the deadline for Overdose Response Strategy Pilot Projects: Interventions to Prevent Overdose at the Intersection of Public Health and Public Safety?
Closed August 30, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.2 million each.
Who has won Research and Data Analysis grants before?
The largest recipients over five fiscal years were University of Baltimore, National Association of County and City Health Officials, National Foundation for the Centers for Disease Control & Prevention, Inc. The program made 10 awards worth $9.2 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)